(CRMZ)
Preview

This is a Preview, click here for the full commercial credit report.
Thallion Pharmaceuticals Inc.
7150 Alexander-Fleming
Phone: (514) 940-3600Montreal, QC  H4S 2C8  CanadaTicker: TLN

Business Summary
Thallion Pharmaceuticals Inc. is a biotechnology company focused on developing new pharmaceutical treatments for under-served markets in oncology and infectious diseases. The Company’s product candidates include two oncology product candidates based on targeted therapies: TLN-4601, a first-in-class small molecule and TLN-232, a peptide, both with potential efficacy in multiple oncology indications, as well as Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections. In May 2008, the Company received authorization from the Therapeutic Products Directorate of Health Canada to initiate a Phase II clinical trial evaluating TLN-4601 as a second line monotherapy treatment for patients with GBM, an advanced form of brain cancer.
(Source: ARS)
 
Financial Information
Financial Ratings:Z'' Score  FRISK Score
Latest Financial Statements
and Analyses:
8/31/2009    Annual Financials    Quarterly Financials    
Current Fiscal Period:3Q 2009
Fiscal Year End:December
Last Audit:11/30/2008
Auditors:KPMG LLP
Audit Opinion:Unqualified
 
Stock Performance
 
News Stories
Date
Headline
1/11/2010Thallion Announces Changes to Executive Management Structure and Board of Directors
34 additional News Stories available in full report.
 
Industries
Type
Code
Description
SectorHEALTHHealthcare
IndustryBIOTRXBiotechnology & Drugs
SIC2835In Vitro And In Vivo Diagnostic Substances
8731Commercial Physical And Biological Research
NAICS325412Pharmaceutical Preparation Manufacturing
54171Research and Development in the Physical, Engineering, and Life Sciences
 
Management

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the BoardLloyd M. Segal451/11/20103/14/2007
Chief Executive OfficerAllan Mandelzys 1/11/20104/24/2007
Chief Financial Officer, Corporate SecretaryMichael Singer 3/14/20073/14/2007
6 additional Management records available in full report.
 
Business Names
Business Name
Ecopia BioSciences Inc.
Thallion Pharmaceuticals Inc.
 
General Information
Number of Employees:37 (As of 11/30/2005)
Outstanding Shares:32,144,316 (As of 10/14/2009)
Shareholders:114 
Stock Exchange:TSE
Fax Number:(514) 228-3622
 

Home | Directory | About Us | Products | Service Options | Pricing | Register | Contact Us | Testimonials | Hours of Availability | Careers | Events | Resources | Investors | Sign In
 
Copyright © by CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.
By using this website, you accept the Terms of Use Agreement.
Contact Us: 845.230.3000